Pharmacokinetics and Bioavailability of Monomethyl Fumarate Following a Single Oral Dose of Bafiertam™ (Monomethyl Fumarate) or Tecfidera® (Dimethyl Fumarate)

Thomas W Lategan, Laurene Wang, Tiffany N Sprague, Franck S Rousseau, Thomas W Lategan, Laurene Wang, Tiffany N Sprague, Franck S Rousseau

Abstract

Background: Tecfidera® (dimethyl fumarate [DMF]) is an approved product for the treatment of relapsing forms of multiple sclerosis. Monomethyl fumarate (MMF) is the only active metabolite of DMF and is responsible for its therapeutic efficacy.

Objective: The objective of this study was to determine whether two Bafiertam™ capsules each containing 95 mg of MMF is bioequivalent to one Tecfidera® capsule containing 240 mg of DMF, a prodrug of MMF.

Methods: This was a single-dose, open-label, randomized, two-way crossover study evaluating two treatments over two periods with a washout interval between treatments. Fifty healthy subjects were randomized to receive a single dose of the test drug MMF 190 mg as 2 × 95 mg delayed-release capsules or the reference drug DMF 240 mg as a 1 × 240-mg delayed-release capsule. Blood samples were obtained prior to dosing and at prespecified time points through 24 h post-dose to determine plasma concentrations of MMF. The pharmacokinetic parameters of MMF were calculated including maximum observed concentration, time to reach maximum observed concentration, apparent half-life of the drug in plasma, AUC0-t which is the area under the plasma concentration-time curve (AUC) from time zero (dosing time) to the last time point, t, with measurable analyte concentration, and AUC0-inf, which is AUC0-t plus the extrapolated AUC from time t to infinity.

Results: The geometric least-squares mean ratios (90% confidence interval) of the test drug MMF vs the reference drug DMF were 96.80% (92.18-101.64), 96.35% (91.81-101.12), and 104.84% (95.54-115.05) for AUC0-t, AUC0-inf, and maximum observed concentration, respectively. Two capsules of Bafiertam™ was safe and generally well tolerated. The most common adverse event for both products was flushing, 60% and 51%, for Bafiertam™ and Tecfidera®, respectively.

Conclusions: Based on the statistical analysis results of the pharmacokinetic parameters of MMF, a single oral dose of two Bafiertam™ DR 95 mg capsules is bioequivalent to a single oral dose of one Tecfidera® DR 240 mg capsule.

Clinical trial registration: This study was retrospectively registered with ClinicalTrials.gov (NCT04570670) on 30 September, 2020.

Conflict of interest statement

Thomas W. Lategan, Tiffany N. Sprague, and Franck S. Rousseau are employees of Banner Life Sciences. Laurene Wang is a paid consultant to Banner Life Sciences.

Figures

Fig. 1
Fig. 1
Mean plasma monomethyl fumarate (MMF) concentration-time profiles following a single oral dose of Bafiertam™ 190 mg (2 × 95 mg) and a single oral dose of Tecfidera® 240 mg. Mean ± standard error of the mean linear and semi-log are displayed in the upper and lower panels, respectively. The lower limit of quantitation−upper limit of quantitation for MMF in plasma was 25–2500 ng/mL. Plasma samples from all 50 subjects and from 49 subjects were assayed and included for Bafiertam™ and Tecidera®, respectively

References

    1. Gold R, Kappos L, Arnold D, Bar-Or A, Giovannoni G, Selmaj K, et al. Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. N Engl J Med. 2012;367(12):1098–1107. doi: 10.1056/NEJMoa1114287.
    1. Fox R, Miller D, Phillips J, Hutchinson M, Havrdova E, Kita M, et al. Placebo controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis. N Engl J Med. 2012;367(12):1087–1097. doi: 10.1056/NEJMoa1206328.
    1. Werdenberg D, Joshi R, Wolffram S, Merkle H, Langguth P. Presystemic metabolism and intestinal absorption of antipsoriatic fumaric acid esters. Biopharm Drug Dispos. 2003;24:259–273. doi: 10.1002/bdd.364.
    1. Chen H, Assmann JC, Krenz A, Rahman M, Grimm M, Christian M, et al. Hydroxycarboxylic acid receptor 2 mediates dimethyl fumarate’s protective effect in EAE. J Clin Investig. 2014;124(5):2188–2192. doi: 10.1172/JCI72151.
    1. Parodi B, Rossi S, Morando S, Cordano C, Bragoni A, Motta C, et al. Fumarates modulate microglia activation through a novel HCAR2 signaling pathway and rescue synaptic dysregulation in inflamed CNS. Acta Neuropathol. 2015;130(2):279–295. doi: 10.1007/s00401-015-1422-3.
    1. Biogen. Tecfidera® (dimethyl fumarate) prescribing information and patient information. 2020. . Accessed 22 June 2020.
    1. US Food and Drug Administration, Center for Drug Evaluation and Research. Clinical pharmacology and biopharmaceutics review. 2013. . Accessed 9 July 2020.
    1. Banner Life Sciences. Biafertam™ (monomethyl fumarate) prescribing information and patient information. 2020. . Accessed 2 Nov 2020.
    1. US Food and Drug Administration, Center for Drug Evaluation and Research. Guidance for industry: bioavailability and bioequivalence studies submitted in NDAs or INDs: general considerations (draft March 2014). . Accessed 9 July 2020.
    1. Hauschke D, Steinijans VW, Diletti E, Burke M. Sample size determination for bioequivalence assessment using a multiplicative model. J Pharmacokinet Biopharm. 1992;20(5):557–561. doi: 10.1007/BF01061471.
    1. Wynn D, Lategan TW, Sprague TN, Rousseau FS, Fox EJ. Monomethyl fumarate has better gastrointestinal tolerability profile compared with dimethyl fumarate. Mult Scler Relat Disord. 2020;45:102335. doi: 10.1016/j.msard.2020.102335.
    1. Gold R, Arnold DL, Bar-Or A, Hutchinson M, Kappos L, Havrdova E, et al. Long-term effects of delayed-release dimethyl fumarate in multiple sclerosis: Interim analysis of ENDORSE, a randomized extension study. Mult Scler J. 2017;23(2):253–265. doi: 10.1177/1352458516649037.
    1. Fox EJ, Vasquez A, Grainger W, Ma TS, von Hehn C, Walsh J, et al. Gastrointestinal tolerability of delayed-release dimethyl fumarate in a multicenter, open-label study of patients with relapsing forms of multiple sclerosis (MANAGE) Int J MS Care. 2016;18:9–18. doi: 10.7224/1537-2073.2014-101.
    1. McCullough T, Annamalai T, Wustrow D, Cundy K. Comparative gastric irritation of the fumaric acid esters dimethyl fumarate (DMF) and XP23829 in rat and monkey. Neurology. 2013;80(7 Suppl.):P01.159.
    1. Rantanen T. The cause of the Chinese sofa/chair dermatitis epidemic is likely to be contact allergy to dimethylfumarate, a novel potent contact sensitizer. Br J Dermatol. 2008;159(1):218–221. doi: 10.1111/j.1365-2133.2008.08622.x.
    1. Silvestre JF, Mercader P, De la Cuadra J, Ballester I, Gallardo F, Pujol RM, et al. Shoe contact dermatitis from dimethyl fumarate: clinical manifestations, patch test results, chemical analysis, and source of exposure. Contact Dermatitis. 2009;61(5):249–260. doi: 10.1111/j.1600-0536.2009.01628.x.
    1. Naismith RT, Wundes A, Ziemssen T, Jasinska E, Freedman MS, Lembo AJ, et al. Diroximel fumarate demonstrates an improved gastrointestinal tolerability profile compared with dimethyl fumarate in patients with relapsing-remitting multiple sclerosis: results from the randomized, double-blind, phase III EVOLVE-MS-2 study. CNS Drugs. 2020;34:185–196. doi: 10.1007/s40263-020-00700-0.

Source: PubMed

Sponsors et collaborateurs

Les conditions médicales

Interventions en matière de drogue

3
S'abonner